Lundbeck/Otsuka win US FDA OK for intramuscular schizophrenia drug Abilify Maintena
This article was originally published in Scrip
Executive Summary
The US FDA on 28 February granted approval to Lundbeck and its partner Otsuka Pharmaceutical to market an intramuscular depot formulation of aripiprazole under the brand-name Abilify Maintena to treat schizophrenia.